Betahistin tablets 24mg, No. 30

• treatment and prevention of vestibular dizziness of various origins;

• syndromes including dizziness and headache, tinnitus, progressive hearing loss, nausea and vomiting;

• disease or Meniere's syndrome.

Inside, during meals.

Tablets 8 mg: 1Ц2 table. 3 times a day.

Tablets 16 mg: 1 / 2-1 table. 3 times a day.

Tablets 24 mg: 1 tab. 2 times a day.

Improvement is usually noted already at the beginning of therapy, a stable therapeutic effect occurs after 2 weeks of treatment and can increase over several months of treatment. The treatment is long-term. The duration of the course of treatment is determined individually.

Active ingredient: betahistine dihydrochloride

Excipients : lactose, microcrystalline cellulose, copovidone VA 64, magnesium stearate.

• children under 18 years of age (due to lack of data);

• hypersensitivity to any component of the drug.

• pregnancy and lactation.

With care: gastrointestinal ulcer (including history), pheochromocytoma, bronchial asthma. These patients should be monitored regularly during treatment.

Clinical and pharmacological group: A drug that improves the microcirculation of the labyrinth, used for pathology of the vestibular apparatus

Pharmaco-therapeutic group: Histamine preparation

pharmachologic effect

Betahistine acts mainly on the histamine H1 and H3 receptors of the inner ear and the vestibular nuclei of the central nervous system. It improves microcirculation and capillary permeability by direct agonistic action on the H1 receptors of the inner ear vessels, as well as indirectly through the action on H3 receptors, and normalizes endolymph pressure in the labyrinth and cochlea. At the same time, betahistine increases blood flow in the basilar artery.

It has a pronounced central effect, being an inhibitor of the H3 receptors of the vestibular nerve nuclei. Improves the conductivity in the neurons of the vestibular nuclei at the level of the brain stem.

The clinical manifestation of these properties is a decrease in the frequency and intensity of dizziness, a decrease in tinnitus, and an improvement in hearing in case of hearing loss.

Pharmacokinetics

It is absorbed quickly. Plasma protein binding is low. Cmax in blood plasma is reached after 3 hours. T1 / 2 is 3-4 hours. It is almost completely excreted by the kidneys in the form of a metabolite (2-peridylacetic acid) within 24 hours.

Indications of the drug Betagistin

• treatment and prevention of vestibular dizziness of various origins;

• syndromes including dizziness and headache, tinnitus, progressive hearing loss, nausea and vomiting;

• disease or Meniere's syndrome.

Dosage regimen

Inside, during meals.

Tablets 8 mg: 1-2 tab. 3 times / day

Tablets 16 mg: 1 / 2-1 tab. 3 times / day

Tablets 24 mg: 1 tab. 2 times / day

Improvement is usually noted already at the beginning of therapy. A stable therapeutic effect occurs after two weeks of treatment and can increase over several months of treatment. The treatment is long-term. The duration of taking the drug is selected individually.

Side effect

Gastrointestinal disorders, the appearance of hypersensitivity reactions from the skin (rash, itching, urticaria), Quincke's edema.

Contraindications for use

• children under 18 years of age (due to lack of data);

• hypersensitivity to any component of the drug.

With care: gastrointestinal ulcer (including history), pheochromocytoma, bronchial asthma. These patients should be monitored regularly during treatment.

Application during pregnancy and lactation

Insufficient data to assess the effects of the drug during pregnancy and lactation. In this regard, it is not recommended to take it during pregnancy. Breastfeeding should be discontinued for the duration of treatment.

Application in children

Contraindication: children under 18 years of age (due to lack of data).

special instructions

Influence on the ability to drive vehicles and mechanisms

Betahistine does not have a sedative effect and does not affect the ability to drive a car or engage in activities that require the speed of psychomotor reactions.

Overdose

Symptoms: nausea, vomiting, convulsions.

Treatment: gastric lavage, intake of activated charcoal, symptomatic therapy.

Drug interactions

Cases of interaction or incompatibility with other drugs are unknown.

Storage conditions of the drug Betagistin

List B. Store in a dry, out of reach of children, protected from light, at a temperature not exceeding 25 ? C.

Shelf life of the drug Betagistin

Shelf life is 2 years. Do not use after the expiration date.

Terms of sale

The drug is available with a prescription.